N/A N=39 Sleep Promotion to Improve Diabetes Management in Adolescents With T1D
Diabetes Mellitus, Type 1
Primary: Sleep Quality: Baseline — 4.3; 4.5 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=212 A Risky Sex Prevention Intervention for Middle School Age Minority Girls
HIV · Risky Sex Prevention
Primary: Adolescent Sexual Activity Index — 1.39; 1.45; 2.12; 1.90 score on a scale — p=0.62
Phase 4 N=5 Regulation of Cervical Mucus Secretion
Fertility · Contraception
Primary: Median Cervical Mucus Score - Baseline — 11; 13 score on a scale
Phase 1 N=16 GSK3640254 First Time in Human (FTIH) Study in Healthy Volunteers
Infection, Human Immunodeficiency Virus · HIV Infections
Primary: Part 1:Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) — 3; 2; 4; 3 Participants
N/A N=83 The Modulatory Effect of Oxytocin on Interoception
Interoception
Primary: Heartbeat Detection (Interoception) Accuracy — 0.637; 0.735 ratio of correct heartbeat counting
Phase 3 N=1,040 Study Evaluating Long-Term Safety of MOA-728 in Participants With Opioid-Induced Constipation
Constipation
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 817; 104 Participants
Phase 2 N=40 Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer
Estrogen Receptor Positive · Postmenopausal · Recurrent Fallopian Tube Carcinoma
Primary: Percentage of Patients Alive and Free of Progression at 12 Weeks (PFS12) — 52.6; 57.9 percentage of patients
Phase 2 N=30 Safety, Pharmacokinetics, and Preliminary Efficacy Study of CDZ173 in Patients With Primary Sjögren's Syndrome
Primary Sjögren's Syndrome
Primary: Number of Participants With Primary Sjögren's Syndrome With Adverse Events and Death up to Day 85 — 20; 8; 1; 0 count of participants
Phase 3 N=124 A Phase III Study to Evaluate the Efficacy and Safety of GSK1358820 in Subjects With Post-stroke Upper Limb Spasticity
Spasticity, Post-Stroke
Primary: Percentage of Participants Who Had Modified Ashworth Scale (MAS) Score Reduced at Least 1 From Baseline in the Elbow Flexors at Week 6 — 50.8; 68.9 Percentage of…
N/A N=245 Virtual Advisors for Physical Activity Promotion in Underserved Communities
Sedentary Lifestyle
Primary: Change in Total Weekly Walking Minutes From Baseline to 12 Months — 134.8; 158.6 minutes per week
Phase 4 N=169 Sayana Press UK Self-Injection Study
Contraception
Primary: Percentage of Successful Self-Injections Performed of All Attempts at Home on Schedule (Full Analysis Set) — 88.8 Percentage of all attempts at home
N/A N=80 Assessment of the Capability of PulmoVista 500 to Continuously Monitor Changes of Ventilation Over Time
Mechanical Ventilation · Single-lung Ventilation · ARDS
Primary: Monitoring Capabilities of PulmoVista 500 — 0.9692; 0.9093 correlation coefficient
N/A N=80 Effect of Feeding Positions of Preterm Infants on Some Physiological Characteristics
Feeding Behavior
Primary: Percentage of Oxygen Saturation — 98.08; 98.09; 96.7; 93.4 SpO2%
N/A N=32 Insulin Sensitivity in Patients With Atopic Dermatitis
Atopic Dermatitis/Eczema · Type 2 Diabetes
Primary: Insulin Sensitivity Difference Between Patients With Atopic Dermatitis and Controls — 9.8; 9.2 mg glucose/kg body mass/minute
Phase 3 N=545 Comparison of CHS-1420 Versus Humira in Subjects With Chronic Plaque Psoriasis
Plaque Psoriasis
Primary: Difference Between the Percentage of Subjects in Each Treatment Group Achieving a 75% Improvement in Psoriasis Area and Severity Index (PASI-75) at Week 12 — 203; 211…